For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted to the intensive care unit ...

GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

GSK and Empirico ink license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases: London, UK Wednesday, October 29, 2025, 09:00 Hr ...

Shortness of breath when walking short distances can occur suddenly or be a chronic condition. It should be evaluated, as it ...

West Ham United Foundation’s recently opened hub in the heart of east London, The Foundry, is helping people with physical ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...

UK pharma major GSK and US clinical-stage biotech Empirico, with leading capabilities in human genetics-driven target ...

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter ...

GSK raised its full-year guidance on Wednesday, after delivering stronger-than-expected third-quarter results, driven by ...

Cash generated from operations totaled £2.5 billion, with free cash flow of £1.2 billion. GSK declared a dividend of 16 pence ...